The effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial - 18/10/18
, Aleksandra Banaszkiewicz c, Jaroslaw Kierkus b, Piotr Landowski d, Anna Korlatowicz-Bilar e, Sabina Wiecek f, Jaroslaw Kwiecien g, Agnieszka Gawronska c, Lukasz Dembinski c, Grazyna Czaja-Bulsa e, h, Piotr Socha bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | What is already known on this subject?
| ||||
• | What are the new findings?
| ||||
• | How might it impact on clinical practice in the foreseeable future?
|
Summary |
Objective |
Constipation is one of the most common problems among children, with a prevalence ranging from 7 to 30%. It is treated with defecation training and laxative medications. However, many patients do not respond to the standard therapy. There is, therefore, an increasing interest in probiotics for the treatment of functional constipation.
Study design |
The aim of this study was to assess the effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional, intractable constipation in children. A double-blind, placebo-controlled, randomized, multicentre trial involved a group of 129 children with functional constipation who were treated with a poor effect for at least two months prior to the study. Patients were randomly assigned to one of the two groups: 1. L. reuteri DSM 17938 and macrogol or 2. macrogol and matching placebo for 8 weeks.
Results |
121 patients completed the study. Almost all patients (119/129) increased their bowel movements in both groups (59 vs 60, ns.) and there was no statistically significant difference in the number of bowel movements per week in week 8 between the study and the placebo group (7.5±3.3 vs 6.9±2.5, respectively). Additionally, there were no significant differences between groups in the numbers of patients complaining of pain during defecation (13/47 vs 8/53), abdominal pain (19/41 vs 25/36), withholding stools (15/45 vs 13/48), passing hard stools (7/53 vs 3/58) or large stools (14/46 vs 12/49), and faecal incontinence (17/43 vs 11/50).
Conclusion |
L. reuteri DSM 17938 supplementation as an additional therapy to macrogol did not have any beneficial effect on the treatment of functional constipation in children aged 3–7 years.
Le texte complet de cet article est disponible en PDF.Keywords : Lactobacillus reuteri DSM 17938, Children, Constipation
Plan
Vol 42 - N° 5
P. 494-500 - octobre 2018 Retour au numéro
Article précédent
- Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care
- Girish Hiremath, Ellyn Kodroff, Mary J. Strobel, Melissa Scott, Wendy Book, Cathy Reidy, Shay Kyle, Denise Mack, Kathleen Sable, Pablo Abonia, Jonathan Spergel, Sandeep K. Gupta, T. Glenn Furuta, Marc E. Rothenberg, Evan S. Dellon
- Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: Two infants treated with sebelipase alfa
- Ermelinda Santos Silva, Maja Klaudel-Dreszler, Agnieska Baku?a, Teresa Oliva, Tereza Sousa, Paula Cristina Fernandes, Anna Tylki-Szyma?ska, Elena Kamenets, Esmeralda Martins, Piotr Socha
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?